For decades, the standard explanation for autoimmune diseases like rheumatoid arthritis has rested on two pillars: inherited genes and environmental triggers. Now, a growing body of research points to a third factor that has largely been overlooked — genetic mutations that immune cells pick up during a person’s lifetime, long after birth.
These acquired changes, known as somatic mutations, have been found at elevated rates in the disease-driving immune cells of patients with rheumatoid arthritis, vasculitis, and giant cell arteritis. The findings, drawn from multiple independent research teams and published across several peer-reviewed journals through 2024, suggest that the immune system’s own genetic evolution may play a direct role in sustaining chronic autoimmune attacks.
A trail of mutations in disease-driving cells
The most detailed mechanistic evidence to date comes from a 2024 study published in Immunity by a team led by researchers at the National Institutes of Health, who used deep single-cell multi-omic tracing to follow pathogenic rheumatoid factor B-cell clones in patients with hepatitis C virus-associated cryoglobulinemic vasculitis. The team identified thousands of somatic mutations within the clones responsible for disease, revealing that three distinct mutagenic processes converge in self-reactive B cells to sustain autoimmune pathology.
Earlier work had already flagged the pattern in rheumatoid arthritis. A 2017 study in Nature Communications led by Savola and colleagues examined clonally expanded cytotoxic T cells in 25 newly diagnosed patients and found somatic mutations in CD8+ T cells of five patients — 20% of the cohort — while only a single mutation appeared in the CD8+ pool among healthy controls. Notably, the mutations were absent from CD4+ T cells, suggesting a selective process tied specifically to the expansion of cytotoxic clones. The sample was small, but the signal was clear enough to prompt larger follow-up investigations.
One of those came in the form of a broader analysis published in Science Advances, which used a 2,533-gene panel on sorted T cells from patients with various hematologic and immunologic disorders. By integrating T-cell receptor sequencing with single-cell data, the researchers showed that the frequency of non-synonymous mutations tracked closely with clonal expansion. The pattern held across multiple disease contexts, suggesting somatic mutations are not a quirk of one condition but a broader phenomenon in which mutated immune cells gain a proliferative advantage.
Specific genes, specific diseases
Two additional studies have zeroed in on individual genes already known from blood cancers. One, indexed in PubMed, used highly sensitive droplet digital PCR to screen rheumatoid arthritis patients for low-frequency activating mutations in STAT3, a gene frequently mutated in T-cell large granular lymphocyte leukemia. The researchers reported a statistically significant increase in STAT3 mutations among rheumatoid arthritis patients compared to controls, with variant allele frequencies that correlated with serological markers of disease activity, including autoantibody levels.
In the vascular autoimmune space, a study published in Arthritis & Rheumatology connected somatic mutations in TET2, a hallmark of age-related clonal hematopoiesis, with giant cell arteritis. That finding is particularly notable because giant cell arteritis disproportionately affects people over 50, the same population in which clonal hematopoiesis becomes increasingly common. Population studies estimate that clonal hematopoiesis of indeterminate potential, or CHIP, affects roughly 10% to 20% of adults over 70, making the overlap between age-related blood cell mutations and late-onset autoimmune disease a pressing question.
What the evidence cannot yet answer
Every study published so far offers a cross-sectional snapshot — a single look at mutations present at the time of diagnosis or sample collection. No longitudinal data yet tracks how somatic mutations accumulate within a patient’s immune system over months or years, or whether that accumulation precedes, coincides with, or follows the clinical onset of symptoms.
That gap matters because it leaves the direction of causality unresolved. The mutations could be drivers that push immune cells toward pathogenic behavior. Or they could be passengers, expanding alongside already-activated clones without directly worsening disease.
The therapeutic implications are similarly uncharted. While STAT3 mutations correlate with serological positivity in rheumatoid arthritis and TET2 mutations associate with giant cell arteritis, no interventional trial has tested whether silencing or correcting these mutations changes disease outcomes. The evidence remains associative, not actionable at the bedside.
An expert commentary published in Arthritis & Rheumatology in 2024 drew a useful distinction between somatic mosaicism, in which mutations exist at low levels across tissues, and CHIP, in which mutated blood stem cells expand with age. The authors described these as related but separable biological processes that may each contribute differently to rheumatic disease, while acknowledging that the field has not yet reached consensus on which mutations matter most or at what threshold they become clinically meaningful.
The range of autoimmune conditions studied so far is also narrow. The primary evidence concentrates on rheumatoid arthritis, cryoglobulinemic vasculitis, and giant cell arteritis. Whether somatic mutations play a comparable role in lupus, multiple sclerosis, type 1 diabetes, or inflammatory bowel disease has not been established with the same rigor.
Technical hurdles add another layer of uncertainty. Detecting low-frequency variants in mixed cell populations requires extremely deep sequencing and careful error correction. Different laboratories use different thresholds for calling a mutation and different gene panels, making it difficult to compare absolute mutation burdens across studies. Most analyses also focus on blood-derived cells, leaving open the question of whether important somatic mutations reside in lymphoid tissues, synovial membranes, or vascular walls where autoimmune damage actually occurs.
Longitudinal tracking and functional validation as next research priorities
As of April 2026, no clinical trials are targeting somatic mutations in autoimmune disease specifically, but the research trajectory is clear. The most informative next steps will likely be longitudinal cohorts that sample patients before disease onset, at diagnosis, and during treatment, tracking how specific mutated clones rise or fall over time. That kind of data could clarify whether somatic mutations are early initiating events, late amplifiers of chronic inflammation, or both.
Parallel functional experiments — editing or silencing recurrent mutations in model systems — will be needed to move from correlation to causation and to test whether targeting mutated clones offers any advantage over existing immunosuppressive therapies. Some researchers have drawn comparisons to precision oncology, where identifying the specific mutations driving a tumor guides treatment selection. Whether a similar approach could work for autoimmune disease remains speculative, but the conceptual framework is already being discussed in the rheumatology literature.
For now, the emerging picture reframes autoimmune diseases as conditions shaped not only by the genetic hand a person is dealt at birth and the environmental exposures they encounter, but also by the mutations their immune cells accumulate along the way. Certain T- and B-cell clones appear to acquire changes that give them a survival or growth edge, allowing them to dominate immune responses and, in some cases, sustain chronic self-reactivity. That recognition does not yet change clinical practice, but it opens a line of investigation that could eventually reshape how autoimmune diseases are diagnosed, monitored, and treated.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
